1. Medtech Insight
  2. >>Business

Myriad's myChoice To Be Used In More Cancer Clinical Trials

Myriad is continuing its mission to expand its companion diagnostics reach by teaming up with Tesaro and Merck to evaluate their breast and ovarian cancer drugs, and expanding its partnership with Abbvie into lung cancer. .

Myriad Genetics Inc. furthered its companion diagnostics cancer play with a new collaboration with drug firms and the expansion of an existing partnership.

Myriad announced Feb. 22 that it has inked a deal with Tesaro Inc. and Merck & Co. Inc....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business